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- A combined approach for assessing GPCR dimer interfaces was developed 
- The method utilizes a HIV-TAT protein transduction motif, MALDI-TOF-MS, and BRET 
- The approach identified Apelin receptor heterodimer interfaces and key dimer residues 
- The method is suitable for GPCR homodimers and heterodimers 
 
Abstract 
The G protein-coupled receptor (GPCR) dimer interface plays an important role in the 
formation and stabilization of the dimer. Therefore, identifying the potential receptor-receptor 
interface is an important part of studying GPCRs. Various strategies have been employed to 
study the GPCR dimer interface and explore its functional significance, but experimental 











optimized experimental and calculation approach for identifying and structurally 
characterizing GPCR dimer interfaces, and constructing atomic resolution models. Using a 
transmembrane domain (TM) peptide containing a human immunodeficiency virus trans-
acting transcriptional activator (HIV-TAT) protein transduction motif, matrix-assisted laser 
desorption tandem time-of-flight mass spectrometry (MALDITOF-MS), and bioluminescence 
resonance energy transfer (BRET), we successfully identified Apelin receptor 
(APJ)/Nociceptin receptor 1 (ORL1) and APJ/Vasopressin receptor 2 (V2R) heterodimer 
interfaces, and two key sites mediating dimerization. This method can identify dimer 
interfaces of GPCR homodimers and heterodimers. 
 
Keywords: G protein-coupled receptor; dimer; interface; transmembrane domain; mass 
spectrometry; bioluminescence resonance energy transfer (BRET) 
 
1. Introduction 
G protein-coupled receptors (GPCRs) can form dimers in cells, and dimeric molecules 
can function in different signal transduction pathways from monomers. As we learn more 
about GPCR dimers, it is becoming increasing apparent that dimerization is important in 
regulating their functions[1]. Interactions between receptors may result in more stable 
structural forms, alter G protein coupling of downstream signals through dimer-specific 
signal transduction, and increase the diversity of GPCR phenotypes[2].  
Many technological advancements have been made in determining GPCR structures, 
and there are now more than 70 crystal structures of individual receptors[3]. However, there 
remain challenges in understanding and exploiting the structures of GPCRs to support drug 
design and the pharmaceutical industry. Emerging evidence suggests that interactions 











In addition to extracellular domains, the transmembrane domain (TM) can also form an 
interface and is important for the formation of head-to-head interfaces in GPCR dimers. The 
receptor interface plays an important role in the formation and stabilization of the dimer, and 
studying the interactions between GPCRs requires the identification of potential receptor-
receptor interfaces[4].  
Different strategies have been employed to study the dimer interfaces of GPCRs and 
explore their functional significance [5], including fluorescence/bioluminescence resonance 
energy transfer (FRET, BRET), cross-linking, co-immunoprecipitation, and computational 
methods. Many of these approaches use inactive and active receptor models obtained from 
dimers determined from structural information. However, numerous experiments and 
calculations are needed to confirm the results. 
Herein, we report a simple and practical approach combining experimental and 
computational methods to identify Apelin receptor (APJ)/Nociceptin receptor 1 (ORL1) and 
APJ/Vasopressin receptor 2 (V2R) heterodimer interfaces, and some key sites mediating 
dimerization. 
 
2. Materials and Methods 
Detailed Materials and Methods are provided in Supporting Information 1. 
2.1 BRET  
For monitoring constitutive APJ and ORL1 interactions, HEK293 cells were transfected with 
APJ-Rluc or APJ mutant-Rluc and ORL1-Venus or ORL1 mutant-Venus plasmids at a ratio 
of 1:3. Coelenterazine h (5 μM) was added for BRET measurements using a Tristar LB941 
plate reader with Rluc (400–475 nm) and Venus (500–550 nm) filters. To determine the 
effects of interfering peptides on APJ/ORL1 dimers, HEK293 cells were co-transfected with 











TM5), stimulated with or without agonists, and detected by BRET assay as described 
previously [6]. 
 
2.2 Design and synthesis of TM peptides 
TM peptides containing the human immunodeficiency virus trans-acting transcriptional 
activator (HIV-TAT) protein transduction peptide and GPCR TM primary sequences were 
prepared (Supplemental Table 1). HIV-TAT (YGRKKRRQRRR) was fused at the N-
terminus of even-numbered TMs and at the C-terminus of odd-numbered TMs to obtain the 
correct orientation of the inserted peptide, since HIV-TAT binds to phosphatidylinositol-(4,5) 
bisphosphate found on the inner surface of the membrane[7]. 
  
2.3 Mass spectrometry (MS) 
MS was performed to identify APJ/ORL1 and APJ/V2R dimer interfaces in samples treated 
with TM peptides. Cells were transfected with APJ, ORL1, or V2R plasmid, incubated for 48 
h, and then treated with the indicated HIV-TAT-TM fused peptides (4 μM) for 60 min at 
37°C. Cells were stimulated with or without ligand (100 nM) for 15 min as required. 
Extracted proteins were immunoprecipitated using anti-APJ, anti-ORL1, and anti-V2R 
antibodies. Protein A/G PLUS agarose beads were incubated with proteins for 2 h, and beads 
were washed four times with lysis buffer. APJ, ORL1, and V2R complexes were analyzed 
using a matrix-assisted laser desorption tandem time-of-flight (MALDI-TOF) mass 
spectrometer as described previously[8]. We also investigated whether the dimeric interface 
changes during receptor activation. Similar methods were used for measuring the activities of 
APJ/ORL1 and APJ/V2R heterodimers after stimulating with corresponding peptide. 
 











We performed calculations to construct atomic resolution models of GPCR dimers. The 3D 
structures of APJ (PDB ID 5VBL)[9] and opioid-related ORL1 (PDB ID 5DHG) were 
retrieved from the Protein Data Bank (PDB) database [10]. The 3D model of V2R was built 
by homology modeling using the homologous GPCR ORL1 (PDB ID 5DHG) as the template. 
Homology modeling was accomplished using MODELLER 9.20[11,12]. Heterodimer models 
of APJ/ORL1 and APJ/V2R, in both active and inactive states, were built by manual protein-
protein docking followed by molecular dynamics simulations using the drug discovery 
software package Discovery Studio 2017 (Supplemental Figure 1). 
 Based on the atomic resolution models of the GPCR dimers, we designed and 
synthesized TM peptides. The APJ/ORL1 and APL/V2R dimer interfaces in samples treated 
with TM peptides were identified by MALDI-TOF MS. Figure 1a shows that ORL1+APJ-
TM1 and ORL1+APJ-TM2 dimers were detected by MS in the absence of ligand, but 
ORL1+APJ-TM5 and ORL1+APJ-TM7 dimers were not detected. This indicates that the 
structural interface of the APJ/ORL1 dimer is composed of TM1 and TM2, and these 
domains interact in an inactive state (without ligand stimulation; Figure 1a). We then 
examined the dynamics of this interface to explore how APJ/ORL1 dimers change interface 
upon activation by Orphanin FQ stimulation. Figure 1b shows that ORL1+APJ-TM5 dimers 
were detected by MS, but ORL1R+APJ-TM4 and ORL1+APJ-TM6 dimers were not detected. 
By contrast, upon Apelin-13 stimulation, APJ/ORL1-TM5 dimers were detected by MS, but 
APJ/ORL1-TM4 and APJ/ORL1-TM6 dimers were not detected in the absence of ligand 
(Figure 1c). These results suggest that the interface of the active APJ/ORL1 dimer switches 
from TM1 and TM2 in the absence of ligand (basal or inactive state) to mainly TM5 in the 
active conformation. 
 The same method was used to identify the interface in the APJ/V2R dimer. As shown 











and the V2R+APJ-TM4 dimer was detected without treatment. By contrast, without treatment, 
V2R TM1 and TM5 did not influence the APJ dimer. When APJ+V2R-TM5 was treated with 
Apelin-13, the results were similar to those of V2R+APJ-TM5 (both were detected; Figure 
1e). These results indicate that TM4 and TM5 are mainly responsible for forming the 
APJ/V2R dimer interface, but TM1 is not intimately involved. Thus, the APJ/V2R 
heterodimer switches from a largely TM4-mediated interface in the inactive state to a largely 
TM5-mediated interface in the active conformation. 
 BRET was used to evaluate the effect of synthetic peptides corresponding to the TM 
region on APJ heterodimer formation. BRET ratios were significantly reduced after 
incubating with HIV-TAT-fused APJ-TM1, TM2, TM4, TM5, and TM6 peptides, but not 
APJ-TM3 and APJ-TM7 peptides (Supplemental Figure 2a). To further confirm the interface, 
each energy donor-acceptor combination was tested by incubating ORL1-TM3 and ORL1-
TM5 with Apelin-13 stimulation, and only the ORL1-TM5 BRET ratio decreased 
(Supplemental Figure 2b). These BRET results are consistent with the MS results (see above). 
The importance of TM1, TM2, and TM5 in the formation of the APJ/ORL1 dimer 
interface was confirmed by constructing point mutations to explore the residues mediating the 
interactions. TM1, TM2, and TM5 mutant receptors of APJ/ORL1 were generated, including 
outward-facing and hydrophobic residues. Plasmids encoding Rluc-tagged APJ and its 
mutants or Venus-tagged ORL1 and its mutants were transfected into HEK-293 cells, and 
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TM5, exhibited significantly lower BRET signals than native APJ or ORL1, further 
highlighting the significance of TM1 and TM2 in the formation of the dimer interface in the 
ligand-free basal (inactive) state (Supplemental Figure 2c). Furthermore, ligand stimulation 
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signals by nearly 50% (Supplemental Figure 2c). These results demonstrate that the key sites 
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 We demonstrated that the APJ/ORL1 heterodimer has a similar structure to the β1-
adrenergic receptor (β1-AR) dimer reported previously[13]. The inactive interface of the 
APJ/ORL1 dimer spans TM1, TM2, and the C-terminus; the active interface includes TM4, 
TM5, and two intracellular loops. Thus, there is a significant conformational change in the 
GPCR protein between inactive and active states, involving a switch between two different 
interfaces. The same method was applied to identify the interface in the APJ/V2R dimer, and 
the results showed that the APJ/V2R heterodimer switches from a largely TM4-mediated 
interface in the basal state to a largely TM5-mediated interface in the active conformation. 
We also identified five key sites in the APJ/ORL1 heterodimer interface. 
 In conclusion, based on the sequence and structural characteristics of GPCRs, we 
generated atomic resolution models of APJ heterodimer interfaces using a combined 
approach involving TM peptides, MALDI-TOF-MS, and BRET. The method is suitable for 
identifying the dimer interfaces of both GPCR heterodimers and homodimers [14]. In future 
work, we will develop additional techniques that are more sensitive and accurate for 
examining GPCR dimerization and interfaces in cells. 
 
Supporting Information 
Supporting Information 1. 
Supplemental Figure 1 and Figure 2. 
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Figure 1. Identification of the interaction interface of APJ/ORL1 and APJ/V2R 
heterodimers using interfering peptides and MS. 
(a) Analysis of the interface between ORL1/APJ heterodimers (without ligand stimulation) 
using interface peptides and MS. ORL1+APJ-TM1 and ORL1+APJ-TM2 dimers were 
detected (TM1 MW = 4067.95, TM2 MW = 4054.84), but ORL1+APJ-TM5 and 
ORL1+APJ-TM7 dimers were not detected. APJ MW = 42.66 kDa, ORL1 MW = 40.5 kDa. 
(b) Analysis of the interface between ORL1/APJ heterodimers (with Orphanin FQ 
stimulation) using interface peptides and MS. ORL1+APJ-TM5 dimers (TM5 MW = 4085.9) 











(c) Analysis of the interface between APJ/ORL1 heterodimers using ORL1-TM5 and MS. 
With Apelin-13 stimulation, the APJ/ORL1-TM5 dimer (TM5 MW = 4109) was detected by 
MS, but the APJ/ORL1-TM5 dimer was not detected in the absence of Apelin-13. 
(d) Analysis of the interface between APJ/V2R heterodimers (with deamino-Cys1 and D-
Arg8-Vasopressin stimulation) using interface peptides and MS.  The V2R+APJ-TM5 dimer 
(TM5 MW = 4085.9) was detected, but the V2R+APJ-TM4 dimer (MW = 3824.75) was not 
detected. Without ligand treatment, the V2R+TM4 dimer was detected, but the V2R+APJ-
TM5 dimer was not detected. 
(e) Without ligand treatment, V2R TM1 (TM1 MW = 3981) and TM5 (TM5 MW = 3794) do 
not influence the APJ dimer. When the APJ+V2R-TM5 dimer was treated with Apelin-13, 
the results were similar to those of V2R+APJ-TM5 (both dimers were detected; V2R-Myc 
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 A combined approach for assessing GPCR dimer interfaces was developed 
 
 The method utilizes a HIV-TAT protein transduction motif, MALDI-TOF-MS, and 
BRET 
 
 The approach identified Apelin receptor heterodimer interfaces, and key dimer 
residues 
 
 The method is suitable for GPCR homodimers and heterodimers 
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